About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Two people familiar with the matter said the U.S. Department of Justice is investigating whether NVIDIA sought to evade antitrust review in last year’s deal with AI chipmaker Groq. Groq described the transaction as a "non-exclusive license agreement"

2026-09-10

Two people familiar with the matter said the U.S. Department of Justice is investigating whether NVIDIA sought to evade antitrust review in last year’s deal with AI chipmaker Groq. Groq described the transaction as a "non-exclusive license agreement" allowing NVIDIA to use chips Groq developed for AI workloads. As part of the arrangement, Groq CEO Jonathan Ross and COO Sunny Madra joined NVIDIA. Regulators note similar licensing-plus-hire deals can be used to sidestep automatic merger reviews designed to assess competitive harm.

Other News
2026-09-10

Individual Stock News 1. Bilibili-W (09626.HK) completed the issuance of US$500 million in convertible preferred notes and simultaneously repurchased approximately US$100 million in Class Z ordinary shares. 2. Dekang Agriculture and Animal Husbandr

Individual Stock News 1. Bilibili-W (09626.HK) completed the issuance of US$500 million in convertible preferred notes and simultaneously repurchased approximately US$100 million in Class Z ordinary shares. 2. Dekang Agriculture and Animal Husbandry (02419.HK) reported sales revenue of RMB 10.74 billion from commercial pig sales in the first eight months. 3. Didi Chuxing-PF (02559.HK): Expects public float to be restored by the end of May 2027. 4. Saijing Technology (00580.HK) plans to participate in the establishment of a joint venture to invest in high-performance TPU AI chip-related businesses. 5. Hengrui Medicine (01276.HK): The National Medical Products Administration accepted the drug marketing authorization application for Repposite Injection. 6. Jiangnan Buyi (03306.HK) released its annual results: profit attributable to shareholders was RMB 997 million, an increase of 11.7% year-on-year. 7. CSPC Pharmaceutical Group (01093.HK): Goserelin sustained-release injection (SYH9102 injection) received clinical trial approval in China. 8. China Energy Engineering Corporation (03996.HK): A subsidiary won the EPC general contracting project for the second phase of the Shaanxi Investment Zhaoshipan Power Plant (2×1000MW units), with a winning bid amount of RMB 6.44326 billion.
2026-09-09

Market news: DeepSeek has commissioned CITIC Securities to prepare for its IPO on the Science and Technology Innovation Board.

Market news: DeepSeek has commissioned CITIC Securities to prepare for its IPO on the Science and Technology Innovation Board.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.